Molecular Medicine 2015

Intravenous Immunoglobulin With Enhanced Polyspecificity Improves Survival In Experimental Sepsis And Aseptic Systemic Inflammatory Response Syndromes

Iglika Djoumerska-Alexieva, Lubka Roumenina, Anastas Pashov, Jordan Dimitrov, Maya Hadzhieva,Sandro Lindig, Elisaveta Voynova, Petya Dimitrova, Nina Ivanovska, Clemens Bockmeyer, Zvetanka Stefanova, Catherine Fitting, Markus Bläss, Ralf Claus, Stephan von Gunten, Srini Kaveri, Jean-Marc Cavaillon, Michael Bauer, and Tchavdar Vassilev

Sepsis is a major cause for death worldwide. Numerous interventional trials with agents neutralizing single proinflammatory mediators have failed to improve survival in sepsis and aseptic systemic inflammatory response syndromes. This failure could be explained by the widespread gene expression dysregulation known as “genomic storm” in these patients. A multifunctional polyspecific therapeutic agent might be needed to thwart the effects of this storm. Licensed pooled intravenous immunoglobulin preparations seemed to be a promising candidate, but they have also failed in their present form to prevent sepsis-related death. We report here the protective effect of a single dose of intravenous immunoglobulin preparations with additionally enhanced polyspecificity in three models of sepsis and aseptic systemic inflammation. The modification of the pooled immunoglobulin G molecules by exposure to ferrous ions resulted in their newly acquired ability to bind some proinflammatory molecules, complement components and endogenous “danger” signals. The improved survival in endotoxemia was associated with serum levels of proinflammatory cytokines, diminished complement consumption and normalization of the coagulation time. We suggest that intravenous immunoglobulin preparations with additionally enhanced polyspecificity have a clinical potential in sepsis and related systemic inflammatory syndromes.

View PDF
Supplemental Data
Posted by Sheila Platt on Mar 31, 2016 10:52 AM CDT